Lynx1 Capital Increases Stake in PASG
Lynx1 Capital Management LP acquired 50,055 shares of PASG, enhancing its position.
Key Points
- Lynx1 Capital Management LP purchased 50,055 shares of PASG on June 25, 2026, for $206,226.60.
- PASG shares traded near $4.85 on Tuesday, with a recent analyst downgrade to 'hold'.
- Renaissance Technologies increased its PASG shares by 24,523, while Yiheng Capital Management boosted its holding by 151%.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Lynx1 Capital Management LP made a substantial move by purchasing 50,055 shares of PASG on June 25, 2026. This transaction was valued at approximately $206,226.60 at an average price of $4.12 per share, signaling a notable increase in their stake.
Other Institutional Activity in PASG
Other institutional investors have also been active in PASG. Renaissance Technologies LLC increased its holdings by 24,523 shares, bringing its total to 133,612 shares valued at about $1,048,854, marking a 22.5% increase. Yiheng Capital Management, L.P. significantly boosted its position by 51,796 shares, ending with 86,097 shares worth approximately $675,861, reflecting a 151% increase. Meanwhile, Vanguard Capital Management LLC opened a new position with 113,964 shares valued at roughly $894,617.
Passage Bio, Inc. Stock Up 7.3%
Shares of PASG traded near $4.85 on Tuesday. The stock has been under scrutiny with recent analyst activity, including a downgrade from Chardan Capital to a 'hold' rating with a price target of $7.0. The stock's movements are closely watched as it navigates market conditions.
$PASG stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Passage Bio, Inc.
Lynx1 Capital Management LP's recent acquisition of 50,055 shares at $4.12 per share adds to the series of insider activities. On May 19, 2026, other insiders like Thomas Richard Kassberg, Dolan Sondhi, Sandip Kapadia, Derrell Porter, and Maxine Gowen each bought 10,539 shares.
Analysts Set New Price Targets
On April 21, 2026, Chardan Capital downgraded PASG to a 'hold' with a $7.0 price target, while Oppenheimer maintained a 'buy' rating with a $15.0 target. Wedbush also downgraded the stock to 'hold' with an $8.0 target. The consensus among analysts remains varied, reflecting differing perspectives on the company's potential.
Bottom Line
Lynx1 Capital's recent purchase of PASG shares indicates a continued interest in the company. While insider activities and analyst ratings vary, these moves provide investors with insights into institutional and expert sentiments. Remember, 13F filings and insider transactions are historical and may not reflect current positions.
Get Passage Bio, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PASG, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.